Literature DB >> 20220775

Functional differences between myeloid leukemia-initiating and transient leukemia cells in Down's syndrome.

J Chen1, Y Li, M Doedens, P Wang, M Shago, J E Dick, J Dick, J K Hitzler.   

Abstract

Children with constitutional trisomy 21 or Down's syndrome (DS) are predisposed to develop myeloid leukemia (ML) at a young age. DS-ML is frequently preceded by transient leukemia (TL), a spontaneously resolving accumulation of blasts during the newborn period. Somatic mutations of GATA1 in the blasts of TL and DS-ML likely function as an initiating event. We hypothesized that the phenotypic difference between TL and DS-ML is due to a divergent functional repertoire of the leukemia-initiating cells. Using an NOD/SCID model, we found that cells initiating DS-ML engrafted, disseminated to distant bone marrow sites, and propagated the leukemic clone in secondary recipients. In contrast, TL cells lacked the ability to expand and to migrate, but were able to persist in the recipient bone marrow. We found some evidence of genomic progression with 1 of 9 DS-ML samples and none of 11 TL samples harboring a mutation of N-RAS. The findings of this pilot study provide evidence for the functional impact of second events underlying the transformation of TL into DS-ML and a needed experimental tool for the functional testing of these promoting events.

Entities:  

Mesh:

Year:  2010        PMID: 20220775     DOI: 10.1038/leu.2010.30

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  5 in total

1.  Low frequency of type-I and type-II aberrations in myeloid leukemia of Down syndrome, underscoring the unique entity of this disease.

Authors:  Marjolein Blink; Marry M van den Heuvel-Eibrink; Valerie de Haas; Jan-Henning Klusmann; Henrik Hasle; C Michel Zwaan
Journal:  Haematologica       Date:  2012-04       Impact factor: 9.941

Review 2.  Evolution of myeloid leukemia in children with Down syndrome.

Authors:  Satoshi Saida
Journal:  Int J Hematol       Date:  2016-02-24       Impact factor: 2.490

3.  Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.

Authors:  April D Sorrell; Todd A Alonzo; Joanne M Hilden; Robert B Gerbing; Thomas W Loew; Lois Hathaway; Dorothy Barnard; Jeffrey W Taub; Yaddanapudi Ravindranath; Franklin O Smith; Robert J Arceci; William G Woods; Alan S Gamis
Journal:  Cancer       Date:  2012-03-05       Impact factor: 6.860

Review 4.  The biology of pediatric acute megakaryoblastic leukemia.

Authors:  Tanja A Gruber; James R Downing
Journal:  Blood       Date:  2015-07-17       Impact factor: 22.113

Review 5.  Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome.

Authors:  Anouchka P Laurent; Rishi S Kotecha; Sébastien Malinge
Journal:  Leukemia       Date:  2020-05-20       Impact factor: 11.528

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.